Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial (vol 41, pg 4852, 2023)

Goto, K.; Goto, Y.; Kubo, T.; Ninomiya, K.; Kim, S.W.; Planchard, D.; ... ; Jänne, P.A. (2024)

Article / Letter to editor

• All authors: Goto, K.; Goto, Y.; Kubo, T.; Ninomiya, K.; Kim, S.W.; Planchard, D.; Ahn, M.J.; Smit, E.F.; Langen, A.J. de; Pérol, M.; Pons-Tostivint, E.; Novello, S.; Hayashi, H.; Shimizu, J.; Kim, D.W.; Kuo, C.H.; Yang, J.C.H.; Pereira, K.; Cheng, F.C.; Taguchi, A.; Cheng, Y.K.; Feng, W.Q.; Tsuchihashi, Z.; Jänne, P.A.
• Date: 2024-02-01
• Journal: Journal of Clinical Oncology
• Volume: 42
• Issue: 4
• Pages: 485 - 485
• DOI: doi:10.1200/JCO.23.02574
• Link: https://ascopubs.org/doi/10.1200/JCO.23.02574